Published • loading... • Updated
McKesson, CD&R Near $5 Billion-Plus Deal to Buy Option Care, FT Reports
The acquisition would expand McKesson’s healthcare services footprint as Option Care shares rose 21% in extended trading, according to the report.
- On Monday, the Financial Times reported that drug distributor McKesson and private equity firm Clayton Dubilier & Rice are nearing a deal to acquire infusion services provider Option Care Health in a transaction valued at more than $5 billion.
- Leerink Partners analyst Michael Cherny said the "strategic rationale" for a deal made sense, as it would expand McKesson's reach beyond physician offices into home and alternate-site care settings.
- McKesson has been reshaping its portfolio, recently purchasing Precision Medicine Group for about $2.25 billion in August; revenue in its oncology and multispecialty segment rose 33% in the latest reported quarter.
- Following the report, Option Care Health shares rose 21% in extended trading, though sources familiar with the matter cautioned that talks could still fall apart.
- Although McKesson, CD&R, and Option Care Health declined to comment, the acquisition would expand the distributor's footprint in providing infusion services that allow patients to receive intravenous medications at home.
Insights by Ground AI
Podcasts & Opinions
14 Articles
14 Articles
CD&R and McKesson agree to acquire Option Care Health in $5.8 billion deal
CD&R and McKesson have agreed to acquire home infusion provider Option Care Health for $32.05 per share in cash, valuing the business at approximately $5.8 billion including debt. The agreement announced October 6 would give CD&R majority ownership and McKesson a substantial minority stake.
McKesson, CD&R near $5 billion-plus deal to buy Option Care ...
·London, United Kingdom
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left1Leaning Right2Center5Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
13%
C 62%
R 25%
Factuality
To view factuality data please Upgrade to Premium
